Scaling for Global Impact
Present—2025
With entry into Phase 3 and our KOSDAQ listing, we have strengthened our foundation to commercialize first-in-class nano-MRI contrast agents and expand into global markets.
Listed on KOSDAQ
INV-003 GLP Nonclinical Study Completed
INV-001 U.S. FDA Phase 2 IND cleared
INV-002 selected as a KDDF Outstanding Project
INV-003 GMP Manufacturing and CMC Development Initiated
INV-003 awarded a KDDF project
U.S. patent granted for core nanomedicine technology (iron-based T1-MRI enabling technology)
INV-002 Phase 3 first patient-in
INV-002 Phase 3 IND approved
Passed KOSDAQ technology assessment (A, BBB)
U.S. patent granted for core nanomedicine technology (nanostructure coating technology)
INV-002 Phase 2b completed and Phase 3 IND submitted
INV-001 Phase 1 completed and advanced to Phase 2a
Drug substance (DS) manufacturing CMO agreement executed (LG Chem)
Clinical Acceleration
2024—2022
As our pipeline advanced into active clinical development, we secured meaningful financing and strategic partnerships to strengthen our commercialization foundation.
INV-002 U.S. FDA Phase 2b IND cleared
R&D investment and exclusive distribution agreement excuted for Inventera’s contrast agents (DongKook Life Science)
Appointed IPO underwriters (NH Investment & Securities, Eugene Investment & Securities)
Completed Series C financing
Selected for Scale-up TIPS program
Corporate name changed (Inventera Pharmaceuticals → Inventera)
INV-001 Phase 1/2a IND approved
Selected for KDDF (Korea Drug Development Fund) Phase 2 program
R&D center relocated to Bangbae-dong HQ
Signed commercialization MOU for Inventera’s contrast agents (DongKook Life Science)
INV-002 Phase 2b IND approved
INV-002 Phase 1/2a clinical study report issued
Acquired 4 international patents for core nanomedicine technology
Completed Series B financing
INV-002 Phase 2a completed
INV-002 Phase 2a first patient-in
Foundation & Validation
2021—2018
After founding the company, we secured the Korean government’s flagship commercialization R&D programs and initiated clinical trials— validating both our technology and execution.
CEO Tae-Hyun Shin recognized by MIT Technology Review (Innovator Under 35)
INV-002 Phase 1 completed
INV-002 Phase 1 first patient-in
INV-001 GMP manufacturing and CMC development initiated
INV-002 Phase 1/2a IRB approved
Selected for UC San Diego GEA program
INV-002 Phase 1/2a IND approved
Completed Series A financing
INV-002 GLP nonclinical studies completed
Established corporate R&D center (Seoul)
Korean patent granted on core nanomedicine technology
Acquired international patent rights for core nanomedicine technology
Selected for TIPS programs
Inventera Pharmaceuticals founded and seed angel investment secured (Chungbuk CCEI)
The Beginning
Inventera's roots trace back to a core nanomedicine invention developed in 2013.
